Rovi/ROVI

€75.35

1.48%
-
1D1W1MYTD1YMAX

About Rovi

Laboratorios Farmaceuticos ROVI SA (ROVI) is a Spain-based company principally engaged in the pharmaceutical industry. The Company’s main activities include the development and commercialization, nationwide and abroad, of medicines and drugs. Its products are structured into three fields: Diagnostic, which offers contrast mediums for use in magnetic resonance, ultrasound and X-ray diagnostics; Prescription, which distributes medicines under such brands as Hibor, Osseor, Hepadren, Pneumovax-23, Glufan, Corlentor, Exxiv, Calcio y Vitamina D3 Rovi and Absorcol, among others; and Over The Counter (OTC), which comprises the Perspirex, Enerzona, Dentimelo and ColdPack brands. The Company owns such fully consolidated subsidiaries as Gineladius SL, Frosst Iberica SA, Rovi Contract Manufacturing SL and Bertex Pharma GmbH, among others.

Ticker

ROVI

Sector

Healthcare

Trading on

BME

Industry

Biotechnology & Drugs

CEO

Juan Lopez-Belmonte Encina

Employees

2,111

Headquarters

Madrid, Spain

Rovi Metrics

BasicAdvanced
€4.07B
Market cap
23.51
P/E ratio
€3.20
EPS
0.56
Beta
€1.10
Dividend rate
1.72%
Dividend yield

What the Analysts think about Rovi

Analyst Ratings

Majority rating from 9 analysts.
Buy

Price Targets

Average projection from 9 analysts.
6.22% downside
High €76.00
Low €66.00
€75.35
Current price
€70.66
Average price target

Rovi Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
23.09% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
€448.6M
109.63%
Net income
€103.6M
98.85%
Profit margin
23.09%
-5.14%

Rovi Earnings Performance

No data availble
Quarterly data is not available. You can look at the annual data instead.

Earnings per share (EPS)

Company profitability
-
QuarterlyAnnual
Actual
Expected
Surprise
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Rovi stock

Buy or sell Rovi stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing